Biocytogen Pharms (Beijing)

Price Chart

Risk-Adjusted Performance

Biocytogen Pharms (Beijing) (2315) Price Performance

Biocytogen Pharms (Beijing) (2315) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at HKD58.55, down 0.76% from the previous close.

Over the past year, 2315 has traded between a low of HKD11.40 and a high of HKD63.50. The stock has gained 413.6% over this period. It is currently 7.8% below its 52-week high.

Biocytogen Pharms (Beijing) has a market capitalization of $39.88B, with a price-to-earnings ratio of 123.16.

About Biocytogen Pharms (Beijing)

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides the customized gene editing services based on animals and cells to meet the needs of basic science research and drug development of the customers; provides the pre-clinical pharmacology service for drug efficacy and toxicity evaluation; engages in breeding and selling animal models for the external and internal use, including set of genetically engineered mice, disease mouse models and aged small animals; engages un utilizing the Group's own antibody discovery platforms to identify antibodies which have the potential to become drug candidates; and engages in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics. The company also offers YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody for the treatment of patients with advanced solid tumors; It also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial. The company has collaboration with Syncromune, Inc.; a license agreement with RemeGen Co., Ltd.; license agreement with Chipscreen NewWay Biosciences. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was founded in 2008 and is headquartered in Beijing, China.

Compare Biocytogen Pharms (Beijing)

Side-by-side comparison against top Healthcare peers.